<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00067184</url>
  </required_header>
  <id_info>
    <org_study_id>HBV98112004</org_study_id>
    <secondary_id>R01DA019934</secondary_id>
    <secondary_id>DPMCDA</secondary_id>
    <nct_id>NCT00067184</nct_id>
  </id_info>
  <brief_title>Fetal Neurobehavioral Development in Methadone Maintained Pregnancies</brief_title>
  <official_title>Methadone, Buprenorphine and Fetal Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine differences in fetal neurobehavior at peak (2 hours
      after oral dose) vs. trough (2 hours before oral dose) maternal plasma methadone levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine differences in fetal neurobehavior at peak (2 hours after oral dose)
      vs. trough (2 hours before oral dose) plasma methadone levels. Anecdotal clinical
      observations suggest that fetal activity is increased at trough methadone levels and
      decreased at peak methadone levels, yet the investigators do not understand how in utero
      methadone exposure affects fetal neurobehavioral state development.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>fetal heart rate</measure>
    <time_frame>120 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fetal movement</measure>
    <time_frame>120 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>neonatal abstinence syndrome</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">157</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Toitu 320/325</intervention_name>
    <description>Fetal monitor</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Methadone exposed pregnancies
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Actively enrolled pregnant patients in CAP SA treatment.

        Inclusion Criteria:

          -  Maternal age 18-40 years

          -  Single intrauterine fetus

          -  Estimated gestational age of 32 weeks

          -  DSMIV criteria for opioid dependence according to e-module of the SCID

          -  Daily methadone maintenance at a stable dose for greater than a week

        Exclusion Criteria:

          -  Concurrent DSMIV axis I diagnosis that would preclude informed consent procedures
             (i.e., schizophrenia, major depression) or confound study outcomes (e.g., Alcohol
             Dependence)

          -  Presence of a serious medical or psychiatric illness requiring chronic medication or
             other intervention (i.e., HIV infection) that may confound data interpretation

          -  Evidence of preterm labor

          -  Evidence of prescription drug use (e.g., antidepressants, tranquilizers)

          -  Presence of major congenital fetal malformation

          -  Recent use (last month) of other illicit drugs (e.g., cocaine, marijuana) based on
             self report or positive on-Trak urine drug toxicology at time of actograph sessions

          -  Split methadone dosing schedule
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren M. Jansson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Addiction and Pregnancy</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jansson LM, Dipietro J, Elko A. Fetal response to maternal methadone administration. Am J Obstet Gynecol. 2005 Sep;193(3 Pt 1):611-7.</citation>
    <PMID>16150250</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2003</study_first_submitted>
  <study_first_submitted_qc>August 12, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2003</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>methadone</keyword>
  <keyword>fetus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

